CGP-6809
CGP-6809 is an orally active DNA inhibitor. CGP-6809 exhibits antitumor activity against various transplantable tumors in mice and rats, including melanoma, prostate cancer, and rectal cancer. CGP-6809 can be used in research on various cancers, including melanoma, prostate cancer, and rectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 70457-70-4
- Formula: C12H23N3O7
- Molecular Weight:321.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 70457-70-4
-
Molecular Weight 321.33
-
Formula C12H23N3O7
-
SMILES
O=NN(C)C(NC[C@H]([C@]1([H])[C@@H]([C@H]([C@H](O1)OCC)O)OC)OC)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
[1]. Schieweck K, et al. CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties. Cancer Chemother Pharmacol. 1989;23(6):341-7. [Content Brief]
[2]. Fiebig HH, et al. CGP 6809--a new nitrosoureido-sugar derivative with activity in human tumor xenografts. Cancer Chemother Pharmacol. 1989;23(6):337-40. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CGP-6809 Related Classifications
HY-19018 Related Classifications
Powered by Bioz